Litigation Details for NORDSTRUM v. MYLAN, INC. (D.N.J. 2017)
✉ Email this page to a colleague
NORDSTRUM v. MYLAN, INC. (D.N.J. 2017)
| Docket | ⤷ Try a Trial | Date Filed | 2017-04-07 |
| Court | District Court, D. New Jersey | Date Terminated | 2017-08-08 |
| Cause | 15:1 Antitrust Litigation | Assigned To | Madeline Cox Arleo |
| Jury Demand | Plaintiff | Referred To | Leda Dunn Wettre |
| Patents | 7,449,012; 7,794,432; 8,048,035; 8,870,827 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in NORDSTRUM v. MYLAN, INC.
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for NORDSTRUM v. MYLAN, INC. (D.N.J. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-04-07 | 1 | holder of Patent No. 7,449,012 B2 (the “‘012 Patent”) and Patent No. 7,794,432 B2 (the “‘432 Patent”) covering…2011, and 2014, Meridian obtained Patent Numbers D543273S1, US 7,449,012 B2, US 7,794,432 B2, US 8,048,035… (D. Del.), alleged infringement of U.S. Patent No. 7,449,012, which is not set to expire until 2025.… “evergreening” the EpiPen device patents (a tactic by which patent holders make minor or insignificant…Meridian obtained the ‘012 Patent on November 11, 2008 and the ‘432 Patent on September 14, 2010. Meridian | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
